SV2C Luminal Domain Polypeptide for Botulinum Neurotoxin A Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Botulinum neurotoxin A (BoNT/A) poses significant neurotoxicity risks due to its potent paralysis-inducing capabilities, with limited effective treatments and detection methods, particularly in identifying substances that reduce its binding to nerve cells and detecting it in various matrices.
Innovation Solution
A polypeptide with an amino acid sequence at least 70% identical to the synaptic vesicle glycoprotein 2C of humans, specifically binding to the HC-fragment of BoNT/A, acts as an antagonist to reduce neurotoxicity and is used for identifying substances that inhibit BoNT/A binding to nerve cells and detecting BoNT/A in different environments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If polypeptide with high sequence identity to SV2C is used to bind BoNT/A, then binding affinity and neurotoxicity reduction are improved, but risk of cross-reactivity with native SV2C and potential disruption of normal synaptic function increases
Solution Approach 1:
The patent extracts and expresses only the luminal domain (amino acids 454-579) of SV2C as a separate, isolated polypeptide. This domain-specific extraction allows the binder to interact with BoNT/A at the receptor binding site without presenting the full transmembrane protein structure, thereby reducing the risk of cross-reactivity with native SV2C while maintaining high binding affinity for the toxin.
Solution Approach 2:
The invention segments the SV2C protein into its luminal domain portion, which is sufficient for BoNT/A binding. By using only this functional segment rather than the complete protein, the patent achieves effective toxin neutralization while minimizing potential interference with normal synaptic vesicle function where the full SV2C protein operates.
2Measurement precision
If full-length SV2C protein is used for detection, then detection sensitivity is improved, but complexity of detection system and difficulty of standardization increase
Solution Approach 1:
The patent extracts the luminal domain of SV2C as the detection element, which retains specific binding capability for BoNT/A. This extracted domain can be produced as a standardized recombinant protein or peptide, simplifying the detection system compared to using full-length transmembrane proteins while maintaining detection sensitivity through specific antigen-antibody or antigen-ligand interactions.
Solution Approach 2:
The invention creates a simplified copy (the luminal domain polypeptide) of the native SV2C receptor that replicates the essential binding function. This copy can be produced in recombinant systems and used in standardized detection assays, eliminating the complexity associated with expressing and handling full-length membrane proteins while preserving detection capability.
3Object-affected harmful factors
If polypeptide binds with high affinity to BoNT/A HC-fragment, then neurotoxicity reduction is improved, but specificity of binding and potential off-target effects become concerns
Solution Approach 1:
The patent applies local quality by focusing the binding interaction on a specific local region - the luminal domain of SV2C that corresponds to the BoNT/A receptor binding site. This localized binding approach ensures high specificity for the toxin's HC-fragment while avoiding interactions with other regions of the toxin or unrelated cellular targets, thereby maintaining both efficacy and specificity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polypeptide effectively inhibits the neurotoxicity of BoNT/A by occupying its receptor binding site, preventing acute intoxication and enabling specific detection of BoNT/A in various matrices through competitive binding studies and immobilization techniques.
Implementation Method 1
the polypeptide binds the HC-fragment of botulinum neurotoxin A provided that the polypeptide is not the synaptic vesicle glycoprotein 2C of homo sapiens
Data Source
AI summary
The invention relates to an isolated polypeptide of the luminal domain of synaptic vesicle glycoprotein 2C of Homo sapiens wherein at least 70 percent of the amino acid sequence is identical to the amino acid sequence of the SV2C of Homo sapiens. The polypeptide binds the HC fragment of botulinum neurotoxin A provided that the polypeptide is not the synaptic vesicle glycoprotein 2C of Homo sapiens.